Rapidly Increasing Hematological Cancer Prevalence among the Population Drives the Global Hematological Cancers Market
Download Exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18482
Rapidly increasing hematological cancer prevalence among the population pool, large investment by key market players, and a number of premium drugs commercially available are the factors driving the global hematological cancers market. According to the National Cancer Institute, globally, hematological cancer is the fifth most commonly occurring cancer and it is the second major cause of death in the U.S. Rich pipeline of products for leukemia is also likely to propel the market post commercialization.
Increasing incidence of hematological cancers is expected to boost the global market in the next few years. However, low prevalence rate of myeloma is expected to hamper the growth of the global hematological cancers market during the forecast period.
The hematological cancers market has been segmented based on treatment, disease indication, and region. In terms of treatment, the hematological cancers market has been categorized into stem cell transplantation, pharmacological therapies, radiation, and surgery therapy. In terms of disease indication, the market has been segmented into leukemia, lymphoma, and myeloma. Prevalence of leukemia is higher than that of lymphoma and myeloma. Moreover, a number of blockbuster, biologically effective drugs are available for the treatment of leukemia. Hence, end-users prefer biological, blockbuster products as compared to chemotherapy drugs.
Geographically, the global hematological cancers market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a significant share of the global hematological cancers market owing to extensive research and development activities in the region. Improvement in reimbursement scenario and rich product pipeline are likely to drive the market in North America through 2024.
Moreover, rising trend of patent protection is expected to boost the hematological cancers market in the next few years. Europe is expected to be the second largest market for hematological cancer treatment in terms of revenue due to enhanced product availability and implementation of cancer treatment alternatives in the region. Favorable reimbursement policies and regulatory framework highly focusing on cancer patient safety are expected to fuel the hematological cancers market in Europe from 2016 to 2024. High awareness about cancer treatment and increasing new product launches for substitute treatment options are the major factors driving the market in Asia Pacific.
Investments by leading pharmaceutical players to develop new drugs is expected to boost the growth of the hematological cancers market in developing countries such as China and India. Countries in Latin America such as Mexico and Brazil are expected to have considerable potential in the hematological cancers market due to increasing cancer treatments and rising health care expenditure.
Browse Full Research Report: http://www.transparencymarketresearch.com/hematological-cancers-market.html
Major players operating in this market include Novartis International AG, Celgene Corporation, AbbVie, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rapidly Increasing Hematological Cancer Prevalence among the Population Drives the Global Hematological Cancers Market here
News-ID: 421748 • Views: 540
More Releases from TMR
Emerging Opportunities in Logistics Market with Current Trends Analysis
The global Logistics market is estimated to attain a valuation of US$ 15,273.21 Bn by the end of 2027, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 4.5% during the forecast period, 2019-2027. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of the
Energy Measurement IC Market is expected to reach US$ 8.39 Bn by the end of 2031
According to a Transparency Market Research (TMR) research report, the global energy measurement ic market is likely to expand at a CAGR of 7.4% during the forecast period, 2022 to 2031. This suggests that the market is expected to reach US$ 8.39 Bn by the end of 2031. The study on the energy measurement ic market adopts rigorous and systematic research approaches to understand the growth dynamic of the market. The
STATCOM UPS Market to Register Double Digit Growth Rate of 16% CAGR by 2024
Over the last decade, rising number of industries and utilities are opting for static synchronous compensator or STATCOM UPS instead of static VAR compensator or SVC UPS. Low harmonic emission coupled with high speed of response is accentuating the expansion of India STATCOM UPS market now and in times to come. Playing a crucial role in voltage control and compensation of reactive power, STATCOM UPS is likely to keep its
Thin Wafer Processing and Dicing Equipment Market US$692.5 mn by 2024 - TMR
Transparency Market Research (TMR) estimates that the global thin wafer processing and dicing equipment market has a highly consolidative landscape. Disco Corp. accounted for largest share of 56.4% in 2015 and likely to be dominant in the coming years. This is creating monopoly in the thin wafer processing and dicing equipment market in terms of competitive presence. The other key players such as EV Group, Plasma-Therm LLC, Lam Research Corp,
More Releases for Hematological
Global Hematological Malignancies Biotherapeutics Market
According to a new market research report published by Global Market Estimates, the Global Hematological Malignancies Biotherapeutics Market is projected to grow at a CAGR value of 10.8% from 2022 and 2027. The hematological malignancies biotherapeutics market is driven mainly by the growing incidence of blood cancer, increasing investment in cancer research, growing cancer awareness initiatives, and the growing number of specialized cancer treatment facilities. Browse 151 Market Data Tables and
Advanced Technologies Of Hematological Disorders Market 2017
Albany, NY, 23rd November : Recent research and the current scenario as well as future market potential of "Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need" globally. The hematological disorders therapy area encompasses non-malignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia. Get PDF for
Hematological Cancers Market 2017 Trends and Review
The Global Hematological Cancers Market Research Report 2017 to 2022 renders deep perception of the key regional market status of the Hematological Cancers Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan. Request for sample of Hematological Cancers Market research report @ https://goo.gl/BeUKBz Split by product type,
Hematological Malignancies Market Is Expected To Profits
Global Hematological Malignancies Market: Snapshot Hematological malignancies, commonly known as hematological cancer, is registering a widespread prevalence across the world. According to the National Cancer Institute, hematological cancer is the fifth most commonly occurring cancer, globally, and is the second prominent reason behind the cancer death in the U.S. Researchers expect the incidence of hematological malignancies to increase further in the coming years, which will result in the growing need for
Hematological Malignancies Market grows with growing prevalence of hematological …
The global hematological malignancies market is highly competitive in nature and is characterized by a consolidated nature, owing to the presence of a few players holding a large share of the overall market, states a research study by Transparency Market Research. The leading players operating in the global market, including Roche, Celgene, Novartis, and AbbVie are anticipated to remain dominant throughout the forecast period. In order to maintain their position
Increasing Incidence of Hematological Cancers is Expected to Boost the Global He …
Hematological cancer, commonly known as hematological malignancy, is a class of cancer that affects the lymph nodes, blood, and bone marrow. It includes numerous forms such as lymphoma, leukemia, and myeloma. Leukemia is a malignancy in which abnormal white blood cells are formed in the bone marrow. Lymphoma is a blood cancer that develops in the lymphatic system. Myeloma is a cancer associated with the plasma of the white blood